MarketCap
Varex Imaging Corporation VREX
$ 10.92
1.87%
Facebook
X
Telegram
Varex Imaging Corporation Revenue | VREX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Varex Imaging Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 845 M | 811 M | 893 M | 859 M | 818 M | 738 M | 781 M | 773 M | 698 M | 620 M | 632 M | 685 M | 670 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 893 M | 620 M | 756 M |
Quarterly Revenue Varex Imaging Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 216 M | 210 M | 210 M | - | 203 M | 213 M | 200 M | - | 209 M | 206 M | 190 M | - | 232 M | 228 M | 206 M | - | 214 M | 215 M | 199 M | - | 211 M | 204 M | 200 M | 568 M | 171 M | 197 M | - | 578 M | 197 M | 196 M | 186 M | 569 M | 191 M | 201 M | 176 M | 482 M | 170 M | 155 M | 157 M | 448 M | 151 M | 157 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 578 M | 151 M | 242 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
64.1 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
LENSAR
LNSR
|
58.4 M | $ 5.6 | -2.78 % | $ 67 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Outset Medical
OM
|
119 M | $ 4.04 | -4.49 % | $ 61.5 K | USA |
 |
AxoGen
AXGN
|
225 M | $ 39.49 | -0.6 % | $ 1.82 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 163.26 | 3.08 % | $ 11.5 B | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Quanterix Corporation
QTRX
|
139 M | $ 3.67 | -6.38 % | $ 156 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 60.45 | -2.74 % | $ 9.18 B | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 1.42 | -6.58 % | $ 3.94 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
TELA Bio
TELA
|
80.3 M | $ 0.69 | -2.81 % | $ 32.4 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Tactile Systems Technology
TCMD
|
330 M | $ 27.48 | 0.15 % | $ 629 M | USA |
 |
TransMedics Group
TMDX
|
605 M | $ 72.26 | 1.59 % | $ 2.46 B | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.89 | -3.38 % | $ 15.1 M | USA |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 17.12 | 1.3 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 14.12 | -2.55 % | $ 400 M | USA |
 |
Viemed Healthcare
VMD
|
270 M | $ 11.77 | 0.86 % | $ 458 M | USA |
 |
Avanos Medical
AVNS
|
701 M | $ 24.99 | 0.04 % | $ 1.16 B | USA |
 |
Beyond Air
XAIR
|
7.68 M | $ 5.16 | -5.67 % | $ 42.8 B | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Xtant Medical Holdings
XTNT
|
134 M | $ 0.43 | -0.39 % | $ 60 M | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.36 | -0.39 % | $ 22.4 M | USA |
 |
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | USA |
 |
Inogen
INGN
|
349 M | $ 6.15 | -2.69 % | $ 164 M | USA |